CASE REPORT article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1629134
This article is part of the Research TopicClinical prediction models in cancer through bioinformaticsView all 13 articles
A case report and literature review of a rare lymphoma with repeated fever and pain, and numbness in both lower limbs
Provisionally accepted
- 1Department of Hematology, Suining Central Hospital, Sichuan Province, Suining, China
- 2Medical Imaging Department of Suining Central Hospital, Sichuan Province, Suining, China
- 3Sichuan Jinyu Medical Inspection Center, Sichuan Province,Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Explore the clinical characteristics, diagnostic and therapeutic strategies, and prognosis of patients with intravascular large B-cell lymphoma (IVLBCL).Methods:Through retrospective analysis of the clinical data of a patient with IVLBCL successfully treated in our department, and in combination with a review of relevant literature, we explore the pathogenesis, diagnostic methods, treatment strategies, and prognostic features of this disease.IVLBCL as a rare subtype of extranodal large B-cell lymphoma, is characterized by high malignancy, strong invasiveness, and poor prognosis. Currently, there is no consensus on the understanding of this disease, and diagnostic and treatment standards are not yet standardized.Diagnosis primarily relies on pathological and immunohistochemical examinations. In this study, the R-CHOP regimen combined with high-dose MTX and orelabrutinib was used to treat IVLBCL patients with central nervous system involvement, achieving good therapeutic effects. However, due to the limited number of cases and the lack of large-scale clinical validation, the efficacy of this treatment regimen still requires further evaluation.
Keywords: IVLBCL, IL-10, Btk inhibitor, CNS invasion, CES 1
Received: 15 May 2025; Accepted: 17 Jul 2025.
Copyright: © 2025 Duan, He, Chen, Jing and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xin Wang, Department of Hematology, Suining Central Hospital, Sichuan Province, Suining, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.